In this regard, Davis et al. [42] have combined the use of GM-CSF with the delivery of LPS, a strong activator of the pattern recognition receptor (PRR) TLR4, achieving an increase in the number of activated antigen-presenting cells in the tumor environment. Here, CSF2 is linked to neoplasm.